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A MANAGED CARE POPULATION
Yu AP, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Clinical trials demonstrated beneﬁts of
HMG-CoA inhibitors (statins) use only after long-term
continuous treatment. However, real-world treatment
compliance treatment is sub-optimal. This study describes
the patterns and risk factors associated with discontinu-
ation in a managed care population. METHODS: Retro-
spective claims from a large California-based managed
care organization were retrieved between December 1997
and June 2000. A total of 25,854 adult patients were
identiﬁed as new statin users during a 1-year identiﬁca-
tion period (with 6 month run-in period, and a null reﬁll
indicator on index date). Discontinuation was deﬁned as
the ﬁrst occurrence when a gap between current ﬁll date
and the last day of the expected supply is greater than 30
days. Medication possession ratios (MPR) were calcu-
lated from index date to the end of each month up to 
one year. Survival analysis was applied to study the risk
factors associated with early discontinuation. Patient
demographics, payer type, previous drug and medical 
utilization, comorbidities, and other risk factors are con-
trolled in the regressions. RESULTS: MPRs were plotted
against time horizon, and the ratios declined faster than
a log-linear fashion, dropping from 74% by month 3 to
57.5% by month 12. By the end of the ﬁrst year, 43.5%
patients have experienced discontinuation. Cox propor-
tional hazard regression revealed that patients initiated
with lovastatin (hazard ratio, HR = 1.39) and simvastatin
(HR = 1.13) are signiﬁcantly more likely to discontinue
than patients on atorvastatin. Patients with FFS plan 
type associated with lower risk of noncompliance than
managed care patients (PPO, POS, HMO). Comorbidity
indicators were unrelated to compliance pattern. Some
types of previous medication use, including ﬁbric acid
derivatives, beta-blocker, antihypertensives, and diuretics,
were associated with higher compliance rate. Patients
who had recent CABG or PTCA tended to have higher
compliance (HR = 0.86, p = 0.02). CONCLUSIONS:
The compliance measured by medication possession ratio
declined rapidly over time. Statin of initial choice (ator-
vastatin), FFS plan type, previous use of other medica-
tions, and previous surgery (CABG/PTCA) were strongly
associated with medication adherence.
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OBJECTIVES: Patients with diabetes are at high risk for
coronary heart disease (CHD) and tight control of lipid
levels is an important clinical objective. In this study, 
we assessed the rate of cholesterol goal attainment 
among patients with diabetes in a managed care setting.
METHODS: A retrospective cohort design was employed
using linked pharmacy, medical, and clinical laboratory
data from members of a Northeastern US group model
HMO. The study cohort included diabetes patients 55+
years of age without CHD who began lipid-lowering drug
therapy between 1995 and 1998. Patients were required
to have had an LDL-C value over 160mg/dL within 90
days before beginning treatment. The change in LDL-C
and the rate of NCEP ATP II goal attainment (LDL <
130mg/dL) were evaluated over 1 year. RESULTS: A total
of 318 patients met study eligibility criteria. The average
age was 68 years and 43% were male. The mean base-
line LDL-C level was 195mg/dL (±28mg/dL) and about
52% of patients had a baseline LDL-C level of 160-189
mg/dL. Ninety-four percent (n = 298) of patients had ≥1
follow-up LDL-C measurements during follow up. The
mean decline in LDL-C was 22% (±14%). The ATP II
treatment goal was reached by 36% of patients. About
50% of patients with baseline LDL-C of 160-189mg/dL
achieved goal versus 21% of patients ≥190mg/dL. Better
adherence to treatment (≥50% of days covered) and more
frequent monitoring of lipid levels were both positively
associated with goal attainment. CONCLUSIONS: In the
mid-to-late 1990s, most patients with diabetes treated for
hyperlipidemia did not achieve their cholesterol goals.
Recent guidelines (NCEP ATP III) have identiﬁed diabetes
patients as a “CHD risk equivalent” with a lower 
cholesterol goal (LDL < 100mg/dL). Further research is
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